Selected References:
- Akmal A, Kung J. 2014. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity. Expert Opin Drug Saf 13(10):1397-1406.
- Alexander EK, et al. 2017. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27(3):315-389.
- American College of Obstetricians and Gynecology. 2020. Thyroid disease in pregnancy. ACOG Practice Bulletin, Number 223. Obstet Gynecol 135(6):e261-e274.
- Andersen SL, et al. 2013. Birth Defects after early pregnancy use of antithyroid drugs: A Danish nationwide study. J Clin Endocrinol Metab 98(11):4374-4381.
- Andersen SL, et al. 2017. Birth Defects after early pregnancy use of antithyroid drugs: A Swedish nationwide study. Euro J Endocrinol 177(4):369-378.
- Andersen SL and Andersen S. 2020. Antithyroid drugs and birth defects. Thyroid Res. 13:11.
- Bahn RS, et al. 2009. The role of propylthiouracil in the management of Graves’ disease in adults: Report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19(7):673-674.
- Burrow GN, et al. 1968. Children exposed in utero to propylthiouracil. Subsequent intellectual and physical development. Am J Dis Child 116: 161-166
- Burrow GN et al. 1978. Intellectual Development in Children Whose Mothers Received Propylthiouracil During Pregnancy. Yale J Biol Med. 51(2): 151–156.
- Burrow GN, Boro ES. 1978. Hyperthyroidism during Pregnancy. N Engl J Med 298(3):150-153.
- Cuff, RD. 2019. Hyperthyroidism during pregnancy: A clinical approach. Clin Obstet Gynecol 62(2):320-329.
- Einstein Z, et al. 1992. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. Eur J Pediatr 151:558-559.
- Gianetti E, et al. 2015. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. J Endocrinol Invest 38(9):977-985.
- Glinoer D, Cooper DS. 2012. The propylthiouracil dilemma. Curr Opin Endocrinol Diabetes Obes 19(5):402-407.
- Heidari R, et al. 2015. An overview on the proposed mechanisms of antithyroid drug-induced liver injury. Adv Pharm Bull 5(1):1-11.
- Howley MM, et al. 2017. Thyroid medication use and birth defects in the National Birth Defects Prevention Study. Birth Defects Res 109(18):1471-1481.
- Hudzik B, Zubelewicz-Szkodzinska B. 2016. Antithyroid drugs during breastfeeding. Clin Endocrinol (Oxf) 85(6):827-830.
- Kancherla V, et al. 2014. Descriptive and risk factor analysis for choanal atresia: The National Birth Defects Prevention Study, 1997-2007. Eur J Med Genet 57(5):220-229.
- Miyamura T, et al. 2013. Acute liver failure associated with propylthiouracil in a pregnant 26-year-old woman. Case Rep Gastroenterol 7(2):240-244.
- Prunty JJ, et al. 2016. Graves’ disease pharmacotherapy in women of reproductive age. Pharmacotherapy 36(1):64-83.
- Romeo AF and Obican SG. 2020. Teratogen Update: Antithyroid Medications. Birth Defects Res. 112(15):1150-1170.
- Seo GH, et al. 2018. Antithyroid drugs and congenital malformations: A nationwide Korean cohort study. Ann Intern Med 168(6):405-413.
- Sequeira E, et al. 2011. Severe propylthiouracil-induced hepatotoxicity in pregnancy managed successfully by liver transplantation: A case report. J Med Case Rep 5:461.
- Taylor P, et al. 2012. A case of propylthiouracil-induced hepatitis during pregnancy. Eur Thyroid J 1(1)41-44.
- Tonacchera M, et al. 2020. Treatment of Graves’ hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy. J Endocrinol Invest. 43(2):257-265.
